• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of gutGutView this articleSubmit a manuscriptReceive email alertsContact usBMJ
Gut. Mar 1998; 42(3): 402–409.
PMCID: PMC1727045

Expression of arylamine N-acetyltransferase in human intestine

Abstract

Background—Arylamine N-acetyltransferases in humans (NAT1 and NAT2) catalyse the acetylation of arylamines including food derived heterocyclic arylamine carcinogens. Other substrates include the sulphonamide 5-aminosalicylic acid (5-ASA), which is an NAT1 specific substrate; N-acetylation of 5-ASA is a major route of metabolism. NAT1 and NAT2 are both polymorphic.
Aims—To investigate NAT expression in apparently healthy human intestines in order to understand the possible role of NAT in colorectal cancer and in the therapeutic response to 5-ASA.
Methods—The intestines of four organ donors were divided into eight sections. DNA was prepared for genotyping NAT1 and NAT2 and enzymic activities of NAT1 and NAT2 were determined in cytosols prepared from each section. Tissue was fixed for immunohistochemistry with specific NAT antibodies. Western blotting was carried out on all samples of cytosol and on homogenates of separated muscle and villi after microdissection.
Results—NAT1 activity of all cytosols was greater than NAT2 activity. NAT1 and NAT2 activities correlated with the genotypes of NAT1 and NAT2 and with the levels of NAT1 staining determined by western blotting. The ratio of NAT1:NAT2 activities showed interindividual variations from 2 to 70. NAT1 antigenic activity was greater in villi than in muscle. NAT1 was detected along the length of the villi in the small intestine. In colon samples there was less NAT1 at the base of the crypts with intense staining at the tips.
Conclusions—The interindividual variation in NAT1 and NAT2 in the colon could affect how individuals respond to exposure to specific NAT substrates including carcinogens and 5-ASA.

Keywords: arylamine N-acetyltransferase; 5-aminosalicylate; colorectal cancer; drug metabolism; inflammatory bowel disease; diet

Full Text

The Full Text of this article is available as a PDF (254K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Weber WW, Hein DW. N-acetylation pharmacogenetics. Pharmacol Rev. 1985 Mar;37(1):25–79. [PubMed]
  • Sim E, Stanley LA, Risch A, Thygesen P. Xenogenetics in multifactorial disease susceptibility. Trends Genet. 1995 Dec;11(12):509–512. [PubMed]
  • Ambrosone CB, Freudenheim JL, Graham S, Marshall JR, Vena JE, Brasure JR, Michalek AM, Laughlin R, Nemoto T, Gillenwater KA, et al. Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. JAMA. 1996 Nov 13;276(18):1494–1501. [PubMed]
  • Vineis P, Bartsch H, Caporaso N, Harrington AM, Kadlubar FF, Landi MT, Malaveille C, Shields PG, Skipper P, Talaska G, et al. Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature. 1994 May 12;369(6476):154–156. [PubMed]
  • Minchin RF, Kadlubar FF, Ilett KF. Role of acetylation in colorectal cancer. Mutat Res. 1993 Nov;290(1):35–42. [PubMed]
  • Sugimura T. Carcinogenicity of mutagenic heterocyclic amines formed during the cooking process. Mutat Res. 1985 Jun-Jul;150(1-2):33–41. [PubMed]
  • Gooderham NJ, Murray S, Lynch AM, Edwards RJ, Yadollahi-Farsani M, Bratt C, Rich KJ, Zhao K, Murray BP, Bhadresa S, et al. Heterocyclic amines: evaluation of their role in diet associated human cancer. Br J Clin Pharmacol. 1996 Jul;42(1):91–98. [PMC free article] [PubMed]
  • Jennne JW. Partial purification and properties of the isoniazid transacetylase in human liver. Its relationship to the acetylation of p-aminosalicylic acid. J Clin Invest. 1965 Dec;44(12):1992–2002. [PMC free article] [PubMed]
  • Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans DA, Grant DM, Hein DW, Lin HJ, Meyer UA, Relling MV, et al. Nomenclature for N-acetyltransferases. Pharmacogenetics. 1995 Feb;5(1):1–17. [PubMed]
  • Wohlleb JC, Hunter CF, Blass B, Kadlubar FF, Chu DZ, Lang NP. Aromatic amine acetyltransferase as a marker for colorectal cancer: environmental and demographic associations. Int J Cancer. 1990 Jul 15;46(1):22–30. [PubMed]
  • Cartwright RA, Glashan RW, Rogers HJ, Ahmad RA, Barham-Hall D, Higgins E, Kahn MA. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet. 1982 Oct 16;2(8303):842–845. [PubMed]
  • Risch A, Wallace DM, Bathers S, Sim E. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol Genet. 1995 Feb;4(2):231–236. [PubMed]
  • Bell DA, Stephens EA, Castranio T, Umbach DM, Watson M, Deakin M, Elder J, Hendrickse C, Duncan H, Strange RC. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res. 1995 Aug 15;55(16):3537–3542. [PubMed]
  • Probst-Hensch NM, Haile RW, Ingles SA, Longnecker MP, Han CY, Lin BK, Lee DB, Sakamoto GT, Frankl HD, Lee ER, et al. Acetylation polymorphism and prevalence of colorectal adenomas. Cancer Res. 1995 May 15;55(10):2017–2020. [PubMed]
  • Probst-Hensch NM, Haile RW, Li DS, Sakamoto GT, Louie AD, Lin BK, Frankl HD, Lee ER, Lin HJ. Lack of association between the polyadenylation polymorphism in the NAT1 (acetyltransferase 1) gene and colorectal adenomas. Carcinogenesis. 1996 Oct;17(10):2125–2129. [PubMed]
  • Bell DA, Badawi AF, Lang NP, Ilett KF, Kadlubar FF, Hirvonen A. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res. 1995 Nov 15;55(22):5226–5229. [PubMed]
  • Hubbard AL, Harrison DJ, Moyes C, Wyllie AH, Cunningham C, Mannion E, Smith CA. N-acetyltransferase 2 genotype in colorectal cancer and selective gene retention in cancers with chromosome 8p deletions. Gut. 1997 Aug;41(2):229–234. [PMC free article] [PubMed]
  • Grant DM, Hughes NC, Janezic SA, Goodfellow GH, Chen HJ, Gaedigk A, Yu VL, Grewal R. Human acetyltransferase polymorphisms. Mutat Res. 1997 May 12;376(1-2):61–70. [PubMed]
  • Ilett KF, Ingram DM, Carpenter DS, Teitel CH, Lang NP, Kadlubar FF, Minchin RF. Expression of monomorphic and polymorphic N-acetyltransferases in human colon. Biochem Pharmacol. 1994 Mar 2;47(5):914–917. [PubMed]
  • Flammang TJ, Westra JG, Kadlubar FF, Beland FA. DNA adducts formed from the probable proximate carcinogen, N-hydroxy-3,2' -dimethyl-4-aminobiphenyl, by acid catalysis or S-acetyl coenzyme A-dependent enzymatic esterification. Carcinogenesis. 1985 Feb;6(2):251–258. [PubMed]
  • Hein DW, Doll MA, Rustan TD, Gray K, Feng Y, Ferguson RJ, Grant DM. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis. 1993 Aug;14(8):1633–1638. [PubMed]
  • Matas N, Thygesen P, Stacey M, Risch A, Sim E. Mapping AAC1, AAC2 and AACP, the genes for arylamine N-acetyltransferases, carcinogen metabolising enzymes on human chromosome 8p22, a region frequently deleted in tumours. Cytogenet Cell Genet. 1997;77(3-4):290–295. [PubMed]
  • Farrington SM, Cunningham C, Boyle SM, Wyllie AH, Dunlop MG. Detailed physical and deletion mapping of 8p with isolation of YAC clones from tumour suppressor loci involved in colorectal cancer. Oncogene. 1996 Apr 18;12(8):1803–1808. [PubMed]
  • Mattano SS, Weber WW. Kinetics of arylamine N-acetyltransferase in tissues from rapid and slow acetylator mice. Carcinogenesis. 1987 Jan;8(1):133–137. [PubMed]
  • Hickman D, Palamanda JR, Unadkat JD, Sim E. Enzyme kinetic properties of human recombinant arylamine N-acetyltransferase 2 allotypic variants expressed in Escherichia coli. Biochem Pharmacol. 1995 Aug 25;50(5):697–703. [PubMed]
  • Stanley LA, Coroneos E, Cuff R, Hickman D, Ward A, Sim E. Immunochemical detection of arylamine N-acetyltransferase in normal and neoplastic bladder. J Histochem Cytochem. 1996 Sep;44(9):1059–1067. [PubMed]
  • Deguchi T, Mashimo M, Suzuki T. Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. J Biol Chem. 1990 Aug 5;265(22):12757–12760. [PubMed]
  • Ware JA, Svensson CK. Longitudinal distribution of arylamine N-acetyltransferases in the intestine of the hamster, mouse, and rat. Evidence for multiplicity of N-acetyltransferases in the intestine. Biochem Pharmacol. 1996 Nov 22;52(10):1613–1620. [PubMed]
  • Stanley LA, Mills IG, Sim E. Localization of polymorphic N-acetyltransferase (NAT2) in tissues of inbred mice. Pharmacogenetics. 1997 Apr;7(2):121–130. [PubMed]
  • Chung JG, Levy GN, Weber WW. Distribution of 2-aminofluorene and p-aminobenzoic acid N-acetyltransferase activity in tissues of C57BL/6J rapid and B6.A-NatS slow acetylator congenic mice. Drug Metab Dispos. 1993 Nov-Dec;21(6):1057–1063. [PubMed]
  • Warren BF, Watkins PE. Animal models of inflammatory bowel disease. J Pathol. 1994 Apr;172(4):313–316. [PubMed]
  • Hill MJ. Aetiology of colorectal cancer: current concepts. Baillieres Clin Gastroenterol. 1989 Jul;3(3):567–592. [PubMed]
  • Schreiber S, Hämling J, Zehnter E, Howaldt S, Daerr W, Raedler A, Kruis W. Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate. Gut. 1997 Jun;40(6):761–766. [PMC free article] [PubMed]

Figures and Tables

Figure 1
Identification of NAT1 alleles by PCR and restriction enzyme digestion with Bsa0I. Template DNA was amplified with the primer pair N539 (sense) and N714 (antisense) and then digested with Bsa0I. The wild type allele (G at position 560 of coding sequence) ...
Figure 2
Detection of NAT enzymic activity in different sections along the length of human intestine. (a) Enzymic acivity of NAT1 was determined in cytosols with p-aminobenzoic acid; (b) NAT2 activity was determined with sulphamethazine. (c) Ratios of activities of ...
Figure 3
Expression of NAT1 in human intestine detected by western blotting. (a) Samples of mucosal cytosol along the length of human intestine from individual 22/3 were prepared and analysed by polyacrylamide gel electrophoresis and western blotting (tracks 2 ...
Figure 4
Expression of NAT in human intestine detected by immunohistochemistry with antiserum 177. Sections of duodenum (a,c) and colon (b,d) were stained with antiserum 177 (diluted 1 in 3000) (a,b) or the corresponding dilutions of preimmune serum (c,d). Intestine ...
Figure 5
Expression of NAT1 in human intestine detected by immunohistochemistry with antiserum 184. Small intestine from individual 22/3 was stained with antiserum 184 (diluted 1/800) (a,c) or with the corresponding dilution of preimmune serum (b,d). Original magnification: ...
Figure 6
Determination of NAT expression in villi and muscle by western blotting. Villi were microdissected from muscle samples of small intestinal samples (corresponding to track 4 of fig 3a) and large intestine (corresponding to track 7 of fig 3a). The mucosa ...

Articles from Gut are provided here courtesy of BMJ Group

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...